63.81
Halozyme Therapeutics Inc stock is traded at $63.81, with a volume of 1.64M.
It is down -0.05% in the last 24 hours and up +7.88% over the past month.
See More
Previous Close:
$63.84
Open:
$63.39
24h Volume:
1.64M
Relative Volume:
1.27
Market Cap:
$7.97B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
21.13
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-0.33%
1M Performance:
+7.88%
6M Performance:
+11.48%
1Y Performance:
+56.86%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
63.81 | 7.97B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-29-24 | Initiated | TD Cowen | Outperform |
Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
Jul-24-23 | Initiated | H.C. Wainwright | Buy |
May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Berenberg | Buy |
Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Dec-21-22 | Resumed | Morgan Stanley | Overweight |
Nov-28-22 | Initiated | Wells Fargo | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Initiated | Evercore ISI | Outperform |
May-17-21 | Initiated | SVB Leerink | Outperform |
May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-21-21 | Reiterated | The Benchmark Company | Buy |
Dec-17-20 | Initiated | Berenberg | Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jul-01-20 | Initiated | The Benchmark Company | Buy |
Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-08-20 | Initiated | Goldman | Buy |
Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-19-18 | Resumed | Piper Jaffray | Neutral |
May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-24-18 | Initiated | Goldman | Neutral |
Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
Nov-03-16 | Initiated | Deutsche Bank | Buy |
Dec-04-15 | Initiated | Wells Fargo | Outperform |
Nov-18-15 | Initiated | Citigroup | Buy |
Sep-22-15 | Initiated | Barclays | Overweight |
Jun-22-15 | Reiterated | JP Morgan | Overweight |
Mar-03-15 | Reiterated | UBS | Buy |
Feb-18-15 | Reiterated | MLV & Co | Buy |
Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters.com
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Zacks Research Issues Negative Outlook for HALO Earnings - Defense World
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN
Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN
Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada
High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance
JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India
Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal
Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India
Halozyme Therapeutics Director Sells 5,000 Shares - TradingView
Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock - MarketBeat
Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock - MarketBeat
Los Angeles Capital Management LLC Has $4.42 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics SVP sells $1.26 million in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Michael Labarre Sells Shares of Halozyme The - GuruFocus.com
Halozyme Therapeutics SVP sells shares totaling $1.26 million By Investing.com - Investing.com South Africa
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):